Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. (Q42991482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Rosario López-Rodríguez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

Jose Ramón Vidal-Castiñeira

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Á Hernández-Bartolomé

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M J Borque

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Y Rodríguez-Muñoz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Martín-Vílchez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Trapero-Marugán

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L García-Buey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P Muñoz de Rueda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L Rodrigo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Salmerón

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Moreno-Otero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P Sanz-Cameno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

25 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

317-324

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23615070%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of hepatitis C virus infection

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Bookmarking the genome: maintenance of epigenetic information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Physical and functional HAT/HDAC interplay regulates protein acetylation balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

HDAC inhibitors as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Histone deacetylases as regulators of inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Phosphorylation-acetylation switch in the regulation of STAT1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

A phosphorylation-acetylation switch regulates STAT1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

SNPStats: a web tool for the analysis of association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

A new standard of care for the treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24

inferred from DOI database lookup

7 January 2021

based on heuristic

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2013.24